Fasudil for the treatment of schizophrenia
US11478482B2 · kind B2 · utility
1Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2022 |
| Grant date | Oct 25, 2022 |
| Priority date | — |
| Expiry date | Jan 31, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an antipsychotic drug comprising fasudil or a pharmaceutically acceptable salt thereof as an active agent for the treatment of schizophrenia, including schizophrenia caused by dysfunction of ARHGAP10.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.